Vericel Corporation (VCEL)
VCEL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$40.30
-0.79% on the day
Market cap
$2.1B
Mid cap
Revenue · 2025
$276.3M
+16.5% on 2024
Net income · 2025
$16.5M
6.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | VCEL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000887359 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | MI |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $276.3M |
| Net income | $16.5M |
| Operating income | $11.0M |
| Net margin | 6.0% |
| Operating margin | 4.0% |
| Revenue growth | +16.5% |
| Cash | $100.1M |
| Total assets | $488.0M |
| P/E (computed) | 124.9× |
| P/S (computed) | 7.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2024-08-16 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-07-30 |
| Latest current report | 8-K | 2026-07-30 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-03-19 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.2% |
| 1 month | +1.3% |
| 3 months | -15.8% |
| Year to date | +11.8% |
| 1 year | +20.2% |
| From 52-week high | -16.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc. | $8.07 | -3.47% | $2.1B |
| RXRX | Recursion Pharmaceuticals Inc. | $3.83 | -4.36% | $2.1B |
| ALVO | Alvotech | $5.38 | -2.18% | $2.1B |
| NVAX | Novavax Inc. | $12.82 | +1.26% | $2.1B |
| ADMA | ADMA Biologics Inc | $10.31 | +1.28% | $2.3B |
| MESO | Mesoblast Limited | $13.89 | -2.63% | $1.8B |
| VIR | Vir Biotechnology Inc. | $10.61 | -6.11% | $1.8B |
| BEAM | Beam Therapeutics Inc. | $24.43 | -2.79% | $2.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier